Matches in SemOpenAlex for { <https://semopenalex.org/work/W2801445145> ?p ?o ?g. }
- W2801445145 endingPage "1323" @default.
- W2801445145 startingPage "1311" @default.
- W2801445145 abstract "Abstract Background Infection of open fractures remains a significant cause of morbidity and mortality to patients worldwide. Early administration of prophylactic antibiotics is known to improve outcomes; however, increasing concern regarding antimicrobial resistance makes finding new compounds for use in such cases a pressing area for further research. CSA-90, a synthetic peptidomimetic compound, has previously demonstrated promising antimicrobial action against Staphylococcus aureus in rat open fractures. However, its efficacy against antibiotic-resistant microorganisms, its potential as a therapeutic agent in addition to its prophylactic effects, and its proosteogenic properties all require further investigation. Questions/purposes (1) Does prophylactic treatment with CSA-90 reduce infection rates in a rat open fracture model inoculated with S aureus , methicillin-resistant S aureus (MRSA), and methicillin-resistant Staphylococcus epidermidis (MRSE) as measured by survival, radiographic union, and deep tissue swab cultures? (2) Does CSA-90 reduce infection rates when administered later in the management of an open fracture as measured by survival, radiographic union, and deep tissue swab cultures? (3) Does CSA-90 demonstrate a synergistic proosteogenic effect with bone morphogenetic protein 2 (BMP-2) in a noninfected rat ectopic bone formation assay as assessed by micro-CT bone volume measurement? (4) Can CSA-90 elute and retain its antimicrobial efficacy in vitro when delivered using clinically relevant agents measured using a Kirby-Bauer disc diffusion assay? Methods All in vivo studies were approved by the local animal ethics committee. In the open fracture studies, 12-week-old male Wistar rats underwent open midshaft femoral fractures stabilized with a 1.1-mm Kirschner wire and 10 µg BMP-2 ± 500 µg CSA-90 was applied to the fracture site using a collagen sponge along with 1 x 10 4 colony-forming units of bacteria ( S aureus /MRSA/MRSE; n = 10 per group). In the delayed treatment study, débridement and treatment with 500 µg CSA-90 were performed at Day 1 and Day 5 after injury and bacterial insult ( S aureus ). All animals were reviewed daily for signs of local infection and/or sepsis. An independent, blinded veterinarian reviewed twice-weekly radiographs, and rats showing osteolysis and/or declining overall health were culled at his instruction. The primary outcome of both fracture studies was fracture infection, incorporating survival, radiographic union, and deep tissue swab cultures. For the ectopic bone formation assay, 0 to 10 µg BMP-2 and 0 to 500 µg CSA-90 were delivered on a collagen sponge into bilateral quadriceps muscle pouches of 8-week-old rats (n = 10 per group). Micro-CT quantification of bone volume and descriptive histologic analysis were performed for all in vivo studies. Modified Kirby-Bauer disc diffusion assays were used to quantify antimicrobial activity in vitro using four different delivery methods, including bone cement. Results Infection was observed in none of the MRSA inoculated open fractures treated with CSA-90 with 10 of 10 deep tissue swab cultures negative at the time of cull. Median survival was 43 days (range, 11-43 days) in the treated group versus 11 days (range, 8-11 days) in the untreated MRSA inoculated group (p < 0.001). However, delayed débridement and treatment of open fractures with CSA-90 at either Day 1 or Day 5 did not prevent infection, resulting in early culls by Day 21 with positive swab cultures (10 of 10 for each time point). Maximal ectopic bone formation was achieved with 500 μg CSA-90 and 10 μg BMP-2 (mean volume, 9.58 mm 3 ; SD, 7.83), creating larger bone nodules than formed with 250 μg CSA-90 and 10 μg BMP-2 (mean volume, 1.7 mm 3 ; SD, 1.07; p < 0.001). Disc diffusion assays showed that CSA-90 could successfully elute from four potential delivery agents including calcium sulphate (mean zone of inhibition, 11.35 mm; SD, 0.957) and bone cement (mean, 4.67 mm; SD, 0.516). Conclusions CSA-90 shows antimicrobial action against antibiotic-resistant Staphylococcal strains in vitro and in an in vivo model of open fracture infection. Clinical Relevance The antimicrobial properties of CSA-90 combined with further evidence of its proosteogenic potential make it a promising compound to develop further for orthopaedic applications." @default.
- W2801445145 created "2018-05-17" @default.
- W2801445145 creator A5011098711 @default.
- W2801445145 creator A5041415750 @default.
- W2801445145 creator A5044116418 @default.
- W2801445145 creator A5046086498 @default.
- W2801445145 creator A5048281051 @default.
- W2801445145 creator A5057503314 @default.
- W2801445145 creator A5067957014 @default.
- W2801445145 creator A5083140994 @default.
- W2801445145 creator A5087374760 @default.
- W2801445145 date "2018-04-26" @default.
- W2801445145 modified "2023-09-23" @default.
- W2801445145 title "CSA-90 Promotes Bone Formation and Mitigates Methicillin-resistant Staphylococcus aureus Infection in a Rat Open Fracture Model" @default.
- W2801445145 cites W1469797763 @default.
- W2801445145 cites W1522457301 @default.
- W2801445145 cites W1979242330 @default.
- W2801445145 cites W1979698207 @default.
- W2801445145 cites W2016366979 @default.
- W2801445145 cites W2016662879 @default.
- W2801445145 cites W2019059930 @default.
- W2801445145 cites W2022684817 @default.
- W2801445145 cites W2060428236 @default.
- W2801445145 cites W2087403130 @default.
- W2801445145 cites W2113282040 @default.
- W2801445145 cites W2115408678 @default.
- W2801445145 cites W2130290558 @default.
- W2801445145 cites W2143256071 @default.
- W2801445145 cites W2162285164 @default.
- W2801445145 cites W2171998389 @default.
- W2801445145 cites W2182126129 @default.
- W2801445145 cites W2203526071 @default.
- W2801445145 cites W2297527134 @default.
- W2801445145 cites W2314952284 @default.
- W2801445145 cites W2509007221 @default.
- W2801445145 cites W4230605501 @default.
- W2801445145 doi "https://doi.org/10.1097/01.blo.0000533624.79802.e1" @default.
- W2801445145 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6263573" @default.
- W2801445145 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/29698291" @default.
- W2801445145 hasPublicationYear "2018" @default.
- W2801445145 type Work @default.
- W2801445145 sameAs 2801445145 @default.
- W2801445145 citedByCount "7" @default.
- W2801445145 countsByYear W28014451452020 @default.
- W2801445145 countsByYear W28014451452021 @default.
- W2801445145 countsByYear W28014451452023 @default.
- W2801445145 crossrefType "journal-article" @default.
- W2801445145 hasAuthorship W2801445145A5011098711 @default.
- W2801445145 hasAuthorship W2801445145A5041415750 @default.
- W2801445145 hasAuthorship W2801445145A5044116418 @default.
- W2801445145 hasAuthorship W2801445145A5046086498 @default.
- W2801445145 hasAuthorship W2801445145A5048281051 @default.
- W2801445145 hasAuthorship W2801445145A5057503314 @default.
- W2801445145 hasAuthorship W2801445145A5067957014 @default.
- W2801445145 hasAuthorship W2801445145A5083140994 @default.
- W2801445145 hasAuthorship W2801445145A5087374760 @default.
- W2801445145 hasBestOaLocation W28014451451 @default.
- W2801445145 hasConcept C126322002 @default.
- W2801445145 hasConcept C141071460 @default.
- W2801445145 hasConcept C2777052132 @default.
- W2801445145 hasConcept C2777949923 @default.
- W2801445145 hasConcept C2779489039 @default.
- W2801445145 hasConcept C4937899 @default.
- W2801445145 hasConcept C501593827 @default.
- W2801445145 hasConcept C523546767 @default.
- W2801445145 hasConcept C54355233 @default.
- W2801445145 hasConcept C71924100 @default.
- W2801445145 hasConcept C86803240 @default.
- W2801445145 hasConcept C89423630 @default.
- W2801445145 hasConcept C94665300 @default.
- W2801445145 hasConceptScore W2801445145C126322002 @default.
- W2801445145 hasConceptScore W2801445145C141071460 @default.
- W2801445145 hasConceptScore W2801445145C2777052132 @default.
- W2801445145 hasConceptScore W2801445145C2777949923 @default.
- W2801445145 hasConceptScore W2801445145C2779489039 @default.
- W2801445145 hasConceptScore W2801445145C4937899 @default.
- W2801445145 hasConceptScore W2801445145C501593827 @default.
- W2801445145 hasConceptScore W2801445145C523546767 @default.
- W2801445145 hasConceptScore W2801445145C54355233 @default.
- W2801445145 hasConceptScore W2801445145C71924100 @default.
- W2801445145 hasConceptScore W2801445145C86803240 @default.
- W2801445145 hasConceptScore W2801445145C89423630 @default.
- W2801445145 hasConceptScore W2801445145C94665300 @default.
- W2801445145 hasIssue "6" @default.
- W2801445145 hasLocation W28014451451 @default.
- W2801445145 hasLocation W28014451452 @default.
- W2801445145 hasLocation W28014451453 @default.
- W2801445145 hasLocation W28014451454 @default.
- W2801445145 hasLocation W28014451455 @default.
- W2801445145 hasOpenAccess W2801445145 @default.
- W2801445145 hasPrimaryLocation W28014451451 @default.
- W2801445145 hasRelatedWork W1839011430 @default.
- W2801445145 hasRelatedWork W1971662600 @default.
- W2801445145 hasRelatedWork W2069401434 @default.
- W2801445145 hasRelatedWork W2138029876 @default.
- W2801445145 hasRelatedWork W2318509744 @default.
- W2801445145 hasRelatedWork W2542017963 @default.
- W2801445145 hasRelatedWork W2755377931 @default.